Last reviewed · How we verify

AMG 073 — Competitive Intelligence Brief

AMG 073 (AMG 073) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcimimetic agent. Area: Endocrinology / Nephrology.

marketed Calcimimetic agent Calcium-sensing receptor (CaSR) Endocrinology / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

AMG 073 (AMG 073) — Amgen. AMG 073 is a calcimimetic agent that allosterically activates the calcium-sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AMG 073 TARGET AMG 073 Amgen marketed Calcimimetic agent Calcium-sensing receptor (CaSR)
Experimental: SNF472 Experimental: SNF472 Sanifit Therapeutics S. A. phase 3 Calcimimetic agent Calcium-sensing receptor (CaSR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcimimetic agent class)

  1. Amgen · 1 drug in this class
  2. Multitude Therapeutics Inc. · 1 drug in this class
  3. Sanifit Therapeutics S. A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMG 073 — Competitive Intelligence Brief. https://druglandscape.com/ci/amg-073. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: